Novel Autoinjector Device

From Autumn 2012 - Spring 2013 I worked with a Cambridge based company who had a new drug delivery device technology. I assisted with their business plan and presentations and  introduced the technology to investors and potential co-development partners in big pharma and medical device companies.

The product platform incorporates a pre-filled syringe, an autoinjector and could evolve into a patch pump product. The platform overcomes many of the problems associated with this range of products including, the use of glues, silicon and tungsten, that can contaminate the drug in storage and the breaking of glass syringes in an autoinjector upon activation due to high spring forces. The platform uses a standard Hypak primary pack and then has some proprietary elements to differentiate it from anything else available.

The value proposition to the Pharma company is strong since there are well recognised problems with drug contamination in storage and syringe breakage on autoinjector activation and these have led to a number of well documented and expensive recalls in recent years.

New larger molecule injectable biologics, that can be quite viscous, require a drug delivery method that still has a fine needle and this platform can provide this.